The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain
Open accessAbstract
BACKGROUND: There is a clear need to develop an objective diagnostic test for Alzheimer disease (AD). Changes in the levels of cerebrospinal fluid (CSF) tau protein and beta-amyloid 42 (Abeta42) peptide in patients with AD have been well documented, but the relationship between these biomarkers and neuropathologic changes in the brain is not established. OBJECTIVE: To study the relationship between antemortem CSF biomarker levels and Alzheimer-type neuropathologic changes in the brain. DESIGN: Cross-sectional study to correlate levels of CSF Abeta42, total tau, and phosphorylated tau protein with neuropathologic changes in the brain. SETTING: Academic research. Patients The study included 123 patients (79 with clinically diagnosed AD, 29 with other dementia, and 15 with other neurologic disease). All underwent clinical evaluation and provided antemortem lumbar CSF samples, and neuropathologic data were collected from September 11, 1990, to March 13, 2003, in the Department of Neuroscience and Neurology, University of Kuopio, Kuopio, Finland. MAIN OUTCOME MEASURES: Levels of CSF Abeta42, total tau, and phosphorylated tau protein were measured using standard commercial immunoassays. Neuropathologic evaluations included the classic silver impregnation method and immunohistochemistry for Abeta, hyperphosphorylated tau, and alpha-synuclein. RESULTS: Cerebrospinal fluid Abeta42 and tau protein levels were related to amyloid load and the presence of neurofibrillary pathologic abnormalities in the brain. Cerebrospinal fluid Abeta42 level correlated inversely with total Abeta load in the brain, and CSF tau level correlated with results of immunohistochemistry for hyperphosphorylated tau and with the presence of neocortical neurofibrillary tangles. In multivariate logistic regression analysis, the number of neuritic plaques in the brain remained a significant predictor of decreased CSF Abeta42 level and of increased CSF tau level. Based on the ratio of phosphorylated tau level to Abeta42 level, sensitivity was 91.6%, and specificity was 85.7%, with an overall accuracy of 90.2% for the presence of pathologic neuritic plaque in the brain. CONCLUSIONS: Cerebrospinal fluid Abeta42 and tau proteins are biomarkers of AD-associated pathologic changes in the brain. The combination of abnormally low CSF Abeta42 level and abnormally high CSF tau level predicted the presence of AD pathologic features with high accuracy. This combination assay may be helpful in diagnosing the presence of AD pathologic changes in the brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A characteristic biomarker profile, defined by reduced levels of Aβ42 in conjunction with elevated t-tau and p-tau, provides a robust biochemical signature for detecting AD pathology and distinguishing it from other neurodegenerative disorders72,73.”
From Artificial intelligence-driven multi-omics approaches in Alzheimer's disease: Progress, challenges, and future directions (2025) · cites this paper as [73]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Given that a CSF Aβ42 concentration lower than 500 pg/mL has been utilized as a reliable threshold for the presence of cerebral Aβ deposition in humans (7, 19, 22, 26)”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The level of CSF P-tau also does correlate with severity of PHF tau accumulation after death [81,150].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [150]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. L., & Stadlan, E. (2011) · Neurology · doi:10.1212/01.wnl.0000400650.92875.cf · Cited by 9,882
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.6.1546 · Cited by 5,047
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Self-citationHansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700
Cited by
Sorted by citations
Items 101–200 of 895
Braak, H., Zetterberg, H., Tredici, K. D., & Blennow, K. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1139-0 · Cited by 148
The emerging role of exosomes in Alzheimer’s disease
Zhang, T., Ma, S., Lv, J., Wang, X., Afewerky, H. K., Li, H. R., & Lu, Y. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101321 · Cited by 141
Kim, H. Y., Kim, H. V., Yoon, J. H., Kang, B. R., Cho, S. M., Lee, S., Kim, J. Y., Kim, J. W., Cho, Y., Woo, J., et al. (2014) · Scientific Reports · doi:10.1038/srep07467 · Cited by 140
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects
Toledo, J. B., Zetterberg, H., van Harten, A. C., Glodzik, L., Martinez-Lage, P., Bocchio-Chiavetto, L., Rami, L., Hansson, O., Sperling, R., Engelborghs, S., et al. (2015) · Brain · doi:10.1093/brain/awv199 · Cited by 136
Combined Plasma Biomarkers for Diagnosing Mild Cognition Impairment and Alzheimer’s Disease
Chiu, M., Yang, S., Horng, H. E., Yang, C., Chen, T., Chieh, J.-J., Chen, H.-H., Chen, T.-C., Ho, C.-S., Chang, S.-F., et al. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400129p · Cited by 136
Hansson, O., Batrla, R., Brix, B., Carrillo, M. C., Corradini, V., Edelmayer, R. M., Esquivel, R. N., Hall, C., Lawson, J., Bastard, N. L., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12316 · Cited by 136
Da, X., Toledo, J. B., Zee, J., Wolk, D. A., Xie, S. X., Ou, Y., Shacklett, A., Parmpi, P., Shaw, L. M. J., Trojanowski, J. Q., et al. (2013) · NeuroImage Clinical · doi:10.1016/j.nicl.2013.11.010 · Cited by 144
Mattsson, N., Lönneborg, A., Boccardi, M., Blennow, K., & Hansson, O. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.02.034 · Cited by 136
Ewers, M., Mattsson, N., Minthon, L., Molinuevo, J. L., Antonell, A., Popp, J., Jessen, F., Herukka, S., Soininen, H., Maetzler, W., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.12.006 · Cited by 133
Self-citationPeptides, Antibodies, Peptide Antibodies and More
Trier, N. H., Hansen, P. B., & Houen, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246289 · Cited by 132
When Does Alzheimer′s Disease Really Start? The Role of Biomarkers
Lloret, A., Esteve, D., Lloret, M.-A., Cervera-Ferri, A., Lopez, B., Nepomuceno, M., & Monllor, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225536 · Cited by 131
Cognitive Decline in Preclinical Alzheimer’s Disease: Amyloid-Beta versus Tauopathy
Huber, C. M., Yee, C., May, T., Dhanala, A., & Mitchell, C. S. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170490 · Cited by 136
Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases
Coughlin, D. G., Hurtig, H. I., & Irwin, D. J. (2019) · Movement Disorders · doi:10.1002/mds.27867 · Cited by 132
Similar amyloid-β burden in posterior cortical atrophy and Alzheimer's disease
de Souza, L. C., Corlier, F. W., Habert, M., Uspenskaya, O., Maroy, R., Lamari, F., Marie Chupin, A., Lehéricy, S., Olivier Colliot, A., Hahn‐Barma, V., et al. (2011) · Brain · doi:10.1093/brain/awr130 · Cited by 134
Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia
Cerami, C., Della Rosa, P. A., Magnani, G., Santangelo, R., Marcone, A., Cappa, S. F., & Perani, D. (2015) · NeuroImage: Clinical · doi:10.1016/j.nicl.2014.12.004 · Cited by 127
CSF tau markers are correlated with hippocampal volume in Alzheimer's disease
de Souza, L. C., Marie Chupin, A., Lamari, F., Jardel, C., Leclercq, D., Olivier Colliot, A., Lehéricy, S., Dubois, B., & Sarazin, M. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.02.022 · Cited by 125
Yang, C., Yang, S., Chieh, J.-J., Horng, H. E., Hong, C., Yang, H.-C., Chen, K. H., Shih, B.-Y., Chen, T., & Chiu, M. (2011) · ACS Chemical Neuroscience · doi:10.1021/cn200028j · Cited by 123
Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers
Hanon, O., Vidal, J., Lehmann, S., Bombois, S., Allinquant, B., Tréluyer, J., Gelé, P., Delmaire, C., Blanc, F., Mangin, J., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.01.004 · Cited by 123
CSF biomarkers for Alzheimer's disease: current utility and potential future use
Holtzman, D. M. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.003 · Cited by 124
Hansson, O., Mikulskis, A., Fagan, A. M., Teunissen, C. E., Zetterberg, H., Vanderstichele, H., Molinuevo, J. L., Shaw, L. M. J., Vandijck, M. L. J., Verbeek, M. M., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.05.008 · Cited by 123
Biomarkers in Alzheimer's disease drug development
Cummings, J. L. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.06.004 · Cited by 122
Harmonized diagnostic criteria for Alzheimer's disease: recommendations
Morris, J. C., Blennow, K., Froelich, L., Nordberg, A. K., Soininen, H. S., Waldemar, G., Wahlund, L., & Dubois, B. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12199 · Cited by 122
Self-citationHypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change
Soldan, A., Pettigrew, C. A., Cai, Q., Wang, M., Moghekar, A., O’Brien, R., Selnes, O. A., & Albert, M. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0194 · Cited by 120
Ramakers, I. H. G. B., Verhey, F. R. J., Scheltens, P., Hampel, H. J., Soininen, H. S., Aalten, P., Rikkert, M. G. M. O., Verbeek, M. M., Spiru, L., Blennow, K., et al. (2012) · Psychological Medicine · doi:10.1017/s0033291712001870 · Cited by 122
Self-citationAlzheimer's disease: The next frontier—Special Report 2017
Karlawish, J. H., Jack, C. R., Rocca, W. A., Snyder, H. M., & Carrillo, M. C. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.02.006 · Cited by 124
Tau as a Biomarker of Neurodegeneration
Holper, S., Watson, R., & Yassi, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137307 · Cited by 121
Sérot, J., Zmudka, J., & Jouanny, P. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-111964 · Cited by 123
Alzheimer’s Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid
Huynh, R. A., & Mohan, C. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00102 · Cited by 112
Kang, J., Vanderstichele, H., Trojanowski, J. Q., & Shaw, L. M. J. (2012) · Methods · doi:10.1016/j.ymeth.2012.03.023 · Cited by 109
Toledo, J. B., Korff, A., Shaw, L. M. J., Trojanowski, J. Q., & Zhang, J. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1148-z · Cited by 106
Biomarkers in Sporadic and Familial Alzheimer’s Disease
Lista, S., O’Bryant, S. E., Blennow, K., Dubois, B., Hugon, J., Zetterberg, H., & Hampel, H. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-143006 · Cited by 106
Zhao, Y., Xin, Y., Meng, S., He, Z., & Hu, W. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.04.014 · Cited by 105
Kam, K., Parekh, A., Sharma, R. A., Andrade, A. G., Lewin, M. P., Castillo, B., Bubu, O. M., Chua, N. J., Miller, M. D., Mullins, A. E., et al. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0309-5 · Cited by 111
A Blood Gene Expression Marker of Early Alzheimer's Disease
Lunnon, K., Sattlecker, M., Furney, S. J., Coppola, G., Simmons, A., Proitsi, P., Lupton, M. K., Lourdusamy, A., Johnston, C., Soininen, H. S., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121363 · Cited by 104
Self-citationPlasma Aβ but Not Tau is Related to Brain PiB Retention in Early Alzheimer’s Disease
Tzen, K., Yang, S., Chen, T., Cheng, T.-W., Horng, H. E., Wen, H.-P., Huang, Y.-Y., Shiue, C., & Chiu, M. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500101j · Cited by 105
Brooks, L., & Loewenstein, D. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt52 · Cited by 107
Mitochondria-Derived Damage-Associated Molecular Patterns in Neurodegeneration
Wilkins, H. M., Weidling, I. W., Ji, Y., & Swerdlow, R. H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00508 · Cited by 102
Novel CSF biomarkers for frontotemporal lobar degenerations
Hu, W. T., Chen‐Plotkin, A. S., Grossman, M., Arnold, S. E., Clark, C. M., Shaw, L. M. J., McCluskey, L. F., Elman, L., Hurtig, H. I., Siderowf, A. D., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e318200d78d · Cited by 101
Babiloni, C., Lizio, R., Percio, C. D., Marzano, N., Soricelli, A., Salvatore, E., Ferri, R., Cosentino, F., Tedeschi, G., Montella, P., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121750 · Cited by 102
Why Vitamin D in Alzheimer's Disease? The Hypothesis
Gezen‐Ak, D., Yılmazer, S., & Dursun, E. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131970 · Cited by 98
Genome-wide interaction analysis of pathological hallmarks in Alzheimer's disease
Wang, H., Yang, J., Schneider, J. A., Jager, P. L. D., Bennett, D. A. A., & Zhang, H. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.04.025 · Cited by 100
Ren, F., Wei, J., Chen, Q., Hu, M., Yu, L., Mi, J., Zhou, X., Qin, D., Wu, J., & Wu, A. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.030 · Cited by 97
Babiloni, C., Percio, C. D., Bordet, R., Bourriez, J., Bentivoglio, M., Payoux, P., Derambure, P., Dix, S. L., Infarinato, F., Lizio, R., et al. (2012) · Clinical Neurophysiology · doi:10.1016/j.clinph.2012.09.017 · Cited by 101
Serum Tau Proteins as Potential Biomarkers for the Assessment of Alzheimer’s Disease Progression
Nam, E., Lee, Y., Moon, C., & Chang, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145007 · Cited by 97
Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease
Leuzy, A., Bollack, A., Pellegrino, D., Teunissen, C. E., Joie, R. L., Rabinovici, G. D., Franzmeier, N., Johnson, K. A., Barkhof, F., Shaw, L. M. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14528 · Cited by 109
Irwin, D. J., Trojanowski, J. Q., & Grossman, M. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00006 · Cited by 96
Grothe, M. J., Moscoso, A., Ashton, N. J., Karikari, T. K., Lantero‐Rodriguez, J., Snellman, A., Zetterberg, H., Blennow, K., Schöll, M., & Initiative, A. D. N. (2021) · Neurology · doi:10.1212/wnl.0000000000012513 · Cited by 99
Popuri, K., Ma, D., Wang, L., & Beg, M. F. (2020) · Human Brain Mapping · doi:10.1002/hbm.25115 · Cited by 96
Preoperative cerebrospinal fluid β‐Amyloid/Tau ratio and postoperative delirium
Xie, Z., Swain, C. A., Ward, S. A. P., Zheng, H., Dong, Y., Sunder, N., Burke, D. W., Escobar, D., Zhang, Y., & Marcantonio, E. R. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.58 · Cited by 96
Comparing 18 F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease
Mattsson, N., Smith, R. A., Strandberg, O. T., Palmqvist, S., Schöll, M., Insel, P. S., Hägerström, D., Ohlsson, T. G., Zetterberg, H., Blennow, K., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000004887 · Cited by 95
Gourmaud, S., Paquet, C., Dumurgier, J., Pace, C., Bouras, C., Gray, F., Laplanche, J., MEURS, E. F., Mouton‐Liger, F., & Hugon, J. (2015) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.140062 · Cited by 95
Boada, M., Anaya, F., Ortiz, P., Olazarán, J., Shua-Haim, J. R., Obisesan, T. O., Hernández, I., Muñoz, J., Buendia, M., Alegret, M., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160565 · Cited by 94
Epilepsy, amyloid-β, and D1 dopamine receptors: a possible pathogenetic link?
Costa, C., Parnetti, L., D'Amelio, M., Tozzi, A., Tantucci, M., Romigi, A., Siliquini, S., Cavallucci, V., Di Filippo, M., Mazzocchetti, P., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.08.025 · Cited by 94
Lockhart, S. N., Baker, S. L., Okamura, N., Furukawa, K., Ishiki, A., Furumoto, S., Tashiro, M., Yanai, K., Arai, H., Kudo, Y., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158460 · Cited by 100
Weigand, S. D., Vemuri, P., Wiste, H. J., Senjem, M. L., Pankratz, V. S., Aisen, P. S., Weiner, M. W., Petersen, R. C., Shaw, L. M., Trojanowski, J. Q., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.08.230 · Cited by 93
Costa‐Rama, E., González-Garcı́a, M. B., & Costa‐García, A. (2014) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2014.05.044 · Cited by 93
Alzheimer’s disease and its treatment–yesterday, today, and tomorrow
Kim, A. Y., Jerdi, S. A., MacDonald, R., & Triggle, C. R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1399121 · Cited by 99
Bendlin, B. B., Carlsson, C. M., Johnson, S. C., Zetterberg, H., Blennow, K., Willette, A. A., Okonkwo, O. C., Sodhi, A., Ries, M. L., Birdsill, A. C., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037720 · Cited by 91
Dysregulated microRNAs in neurodegenerative disorders
Lau, P., & Strooper, B. D. (2010) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2010.01.009 · Cited by 93
Perani, D., Cerami, C., Caminiti, S. P., Santangelo, R., Coppi, E., Ferrari, L. D., Pinto, P., Passerini, G., Falini, A., Iannaccone, S., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3170-y · Cited by 91
Cerebrospinal Fluid Aβ to Tau Ratio and Postoperative Cognitive Change
Xie, Z., McAuliffe, S., Swain, C. A., Ward, S. A. P., Crosby, C. A., Zheng, H., Sherman, J. C., Dong, Y., Zhang, Y., Sunder, N., et al. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e318298b077 · Cited by 92
CSF tau and β-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders
Irwin, D. J., Xie, S. X., Coughlin, D. G., Nevler, N., Akhtar, R. S., McMillan, C. T., Lee, E. B., Wolk, D. A., Weintraub, D. A., Chen‐Plotkin, A. S., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005166 · Cited by 94
An Organ System-Based Synopsis of Pseudomonas aeruginosa Virulence
Morin, C. D., Déziel, É., Gauthier, J., Lévesque, R. C., & Lau, G. W. (2021) · Virulence · doi:10.1080/21505594.2021.1926408 · Cited by 93
Alcolea, D. A., Vilaplana, E., Pegueroles, J., Montal, V., Sánchez‐Juan, P., González‐Suárez, A., Pozueta, A., Rodríguez‐Rodríguez, E., Bartrés‐Faz, D., Dídac Vidal-piñeiro, A., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.03.001 · Cited by 90
Toledo, J. B., Bjerke, M., Da, X., Landau, S. M., Foster, N. L., Jagust, W., Jack, C., Weiner, M., Davatzikos, C., Shaw, L. M., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4829 · Cited by 88
Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease
Leuzy, A., Cullen, N. C., Mattsson, N., & Hansson, O. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000904 · Cited by 91
Tau Transgenic Mice as Models for Cerebrospinal Fluid Tau Biomarkers
Barten, D. M., Cadelina, G. W., Hoque, N., DeCarr, L. B., Guss, V. L., Yang, L., Sankaranarayanan, S., Wes, P. D., Flynn, M. E., Meredith, J. E., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110161 · Cited by 94
Teichmann, M., Epelbaum, S., Samri, D., Lévy, M., Michon, A., Hampel, H. J., Lamari, F., & Dubois, B. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.12.014 · Cited by 89
Tosun, D., Veitch, D. P., Aisen, P. S. S., Jack, C. R., Jagust, W. J., Petersen, R. C., Saykin, A. J., Bollinger, J., Ovod, V., Mawuenyega, K. G., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab008 · Cited by 86
Cerebrospinal Fluid Biomarkers of Alzheimer's Disease
Fagan, A. M., & Holtzman, D. M. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.83 · Cited by 88
CSF biomarkers in posterior cortical atrophy
Seguin, J., Formaglio, M., Perret‐Liaudet, A., Quadrio, I., Tholance, Y., Rouaud, O., Thomas-Antérion, C., Croisile, B., Mollion, H., Moreaud, O., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821ccc98 · Cited by 84
EEG time signature in Alzheimer´s disease: Functional brain networks falling apart
Smailović, U., Koenig, T. W., Laukka, E. J., Kalpouzos, G., Andersson, T., Winblad, B. G., & Jelić, V. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.102046 · Cited by 86
Llorens, F., Schmitz, M., Karch, A., Cramm, M., Lange, P., Gherib, K., Varges, D., Schmidt, C., Zerr, I., & Stoeck, K. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.10.009 · Cited by 84
Extracellular Tau and Its Potential Role in the Propagation of Tau Pathology
Yamada, K. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00667 · Cited by 86
The Complex Role of Apolipoprotein E in Alzheimer’s Disease: an Overview and Update
Mahoney‐Sanchez, L., Belaidi, A. A., Bush, A. I., & Ayton, S. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-016-0839-z · Cited by 84
Iaccarino, L., Burnham, S. C., Dell’Agnello, G., Dowsett, S. A., & Epelbaum, S. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.43 · Cited by 87
Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer’s Disease
Pradeepkiran, J. A., Baig, J., Islam, M. A., Kshirsagar, S., & Reddy, P. H. (2024) · Aging and Disease · doi:10.14336/ad.2024.0286 · Cited by 87
Kokkonen, N., Herukka, S., Huilaja, L., Kokki, M., Koivisto, A. M., Hartikainen, P. H., Remes, A. M., & Tasanen, K. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.09.010 · Cited by 81
Self-citationThe corticobasal syndrome–Alzheimer’s disease conundrum
Hassan, A., Whitwell, J. L., & Josephs, K. A. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.153 · Cited by 80
Shekhar, S., Kumar, R. K., Rai, N., Kumar, V. L., Singh, K. K., Upadhyay, A. D., Tripathi, M., Dwivedi, S. N., Dey, A. B., & Dey, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159099 · Cited by 80
β‐Amyloid aggregation and heterogeneous nucleation
Srivastava, A. K., Pittman, J. M., Zerweck, J., Venkata, B. S., Moore, P. C., Sachleben, J. R., & Meredith, S. C. (2019) · Protein Science · doi:10.1002/pro.3674 · Cited by 82
Korecka, M., & Shaw, L. M. J. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15465 · Cited by 82
Starks, E. J., O’Grady, J. P., Hoscheidt, S. M., Racine, A. M., Carlsson, C. M., Zetterberg, H., Blennow, K., Okonkwo, O. C., Puglielli, L., Asthana, S., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150072 · Cited by 82
11C-PiB Imaging of Human Immunodeficiency Virus–Associated Neurocognitive Disorder
Ances, B. M. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.761 · Cited by 78
Mitochondrial DNA signals driving immune responses: Why, How, Where?
Giordano, L., Ware, S. A., Lagranha, C. J., & Kaufman, B. A. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02042-0 · Cited by 82
Lista, S., Garaci, F., Ewers, M., Teipel, S. J., Zetterberg, H., Blennow, K., & Hampel, H. J. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.04.506 · Cited by 78
The Controversial Role of 24-S-Hydroxycholesterol in Alzheimer’s Disease
Gamba, P., Giannelli, S., Staurenghi, E., Testa, G., Sottero, B., Biasi, F., Poli, G., & Leonarduzzi, G. (2021) · Antioxidants · doi:10.3390/antiox10050740 · Cited by 70
Okonkwo, O. C. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.118 · Cited by 78
Babiloni, C., Percio, C. D., Lizio, R., Marzano, N., Infarinato, F., Soricelli, A., Salvatore, E., Ferri, R., Bonforte, C., Tedeschi, G., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.06.019 · Cited by 78
Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting
Dumurgier, J., Vercruysse, O., Paquet, C., Bombois, S., Chaulet, C., Laplanche, J., Peoc’h, K., Schraen‐Maschke, S., Pasquier, F., Touchon, J., et al. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.06.006 · Cited by 75
Guzman, V. A., Carmichael, O. T., Schwarz, C. G., Tosto, G., Zimmerman, M. E., Brickman, A. M., & Initiative, A. D. N. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.11.009 · Cited by 77
The Role of Genetics in Advancing Precision Medicine for Alzheimer’s Disease—A Narrative Review
Freudenberg‐Hua, Y., Li, W., & Davies, P. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00108 · Cited by 80
A Review of Oxidative Stress Products and Related Genes in Early Alzheimer’s Disease
Cioffi, F., Adam, R. H. I., Bansal, R., & Broersen, K. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210497 · Cited by 73
Yang, S., Chiu, M., Chen, T., & Horng, H. E. (2017) · Neurology and Therapy · doi:10.1007/s40120-017-0075-7 · Cited by 74
Kim, H., Lee, J. U., Kim, S., Song, S., & Sim, S. J. (2019) · ACS Sensors · doi:10.1021/acssensors.8b01242 · Cited by 73
Clinical Guidelines for Cognitive Disorders in Elderly and Older Patients
Bogolepova, A. N., Васенина, Е. Е., Gomzyakova, N. A., Gusev, E. I., Dudchenko, N. G., Emelin, А. Y., Zalutskaya, N. M., Isaev, R. I., Kotovskaya, Y. V., Levin, O. S., et al. (2021) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20211211036 · Cited by 72
Mollenhauer, B., Parnetti, L., Rektorová, I., Kramberger, M. G., Pikkarainen, M., Schulz‐Schaeffer, W., Aarsland, D., Svenningsson, P., Farotti, L., Verbeek, M. M., et al. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13390 · Cited by 73
A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes
Lleó, A., Irwin, D. J., Illán-Gala, I., McMillan, C. T., Wolk, D. A., Lee, E. B., Van Deerlin, V. M., Shaw, L. M., Trojanowski, J. Q., & Grossman, M. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0118 · Cited by 71
Weaver, N. A., Doeven, T., Barkhof, F., Biesbroek, J. M., Groeneveld, O. N., Kuijf, H. J., Prins, N. D., Scheltens, P., Teunissen, C. E., van der Flier, W. M., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.08.001 · Cited by 71
Bertoux, M., de Souza, L. C., Sarazin, M., Funkiewiez, A., Dubois, B., & Hornberger, M. (2014) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000023 · Cited by 71
Metadata
- Authors
- Tapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T.
- Affiliations
- University of Eastern Finland (FI)
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2009-03-01
- Volume
- 66
- Issue
- 3
- Pages
- 382-9
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2075193321
- Cited by
- 896
- References
- 29
- Citations by year
- 2026: 18 · 2025: 27 · 2024: 45 · 2023: 27 · 2022: 34 · 2021: 78 · 2020: 89 · 2019: 75 · 2018: 60 · 2017: 59 · 2016: 51 · 2015: 65 · 2014: 48 · 2013: 63 · 2012: 41
- FWCI
- 32.16
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Archives of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Kuopion Yliopistollinen Sairaala
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, cerebrospinal fluid biomarkers, amyloid-beta 42, tau protein, phosphorylated tau, amyloid plaques, neurofibrillary tangles, diagnostic accuracy, lumbar CSF, neurodegeneration, alpha-synuclein, postmortem neuropathology, biomarker ratios, sensitivity and specificity
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Brain, Cross-Sectional Studies, Dementia, Female, Humans, Immunoassay, Male, Nervous System Diseases, Peptide Fragments, Retrospective Studies, ROC Curve, Logistic Models, Amyloid beta-Peptides, Silver Staining, tau Proteins, Statistics, Nonparametric, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
